Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy

Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) will present three posters at the 29th Annual Congress of the European Society of Gene & Cell Therapy from October 11-14, 2022, in Edinburgh, Scotland. The presentations focus on advancements in AAV gene therapy, including an engineered BBB-penetrant capsid family and evaluations of dose-response and production methodologies for AAV-based therapies. These developments may enhance treatment for neurological disorders, showcasing the company's commitment to innovation in gene therapy.

Positive

• Presentation of three posters at a significant industry conference highlights the company's research and innovation in gene therapy.
• Focus on advancements in AAV capsid technology may position Voyager Therapeutics favorably within the gene therapy market.

Negative

• None.

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it will present three posters at the upcoming 29^th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh, Scotland.

Poster Presentation Details:

Presentation Title: Identification of a Cell Surface Receptor Utilized by an Engineered BBB-Penetrant Capsid Family with Enhanced Brain Tropism in Non-Human Primates and Mice
Poster Number: P024
Presenting Author: Brett Hoffman, Ph.D., Senior Scientist, Capsid Discovery

Presentation Title: Dose-Response Evaluation of 9P801, an Engineered AAV Capsid with High BBB Penetration and CNS Transduction in Non-Human Primates
Poster Number: P015
Presenting Author: Mathieu Nonnenmacher, Ph.D., Vice President, Capsid Discovery

Presentation Title: Evaluation of an Early, Late, Very Late Expressed Rep in a Recombinant Baculovirus to Produce a More Potent AAV-based Gene Therapeutic in Insect Cells
Poster Number: P065
Presenting Author: Jeffrey Slack, Ph.D., Principal Scientist, Cell Culture Development

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from the Company’s TRACER discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas. voyagertherapeutics.com  LinkedIn  Twitter

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

Contacts
Investors
Investors@vygr.com

Media
Peg Rusconi
prusconi@vergescientific.com

FAQ

What is the significance of Voyager Therapeutics presenting at the ESGCT 2022?

Voyager Therapeutics' presence at ESGCT 2022 underscores its commitment to advancing gene therapy research, particularly in neurological disorders.

What topics will Voyager Therapeutics present at the ESGCT congress?

Voyager Therapeutics will present on AAV capsid technology, including a BBB-penetrant capsid and dose-response evaluations of gene therapies.

When is the ESGCT 2022 conference where VYGR will present?

The ESGCT 2022 conference takes place from October 11-14, 2022, in Edinburgh, Scotland.

How does Voyager Therapeutics' research impact its stock VYGR?

The research presented at industry conferences can enhance investor confidence in VYGR by showcasing the company's innovations and potential in gene therapy.